Rebound Seen Predelivery After HIV Suppression in Pregnancy

Share this content:
Rebound Seen Predelivery After HIV Suppression in Pregnancy
Rebound Seen Predelivery After HIV Suppression in Pregnancy

FRIDAY, Aug. 11, 2017 (HealthDay News) -- Women achieving HIV viral suppression in pregnancy can experience viral load rebound predelivery, according to a study published in the September issue of Obstetrics & Gynecology.

Isabelle Boucoiran, M.D., from the University of British Columbia in Vancouver, Canada, and colleagues used a Canadian provincial perinatal HIV database (1997 to 2015) to identify patients who had a live birth, received combination antiretroviral therapy for at least four weeks, had viral load measured within one month of delivery, and had at least one previous undetectable viral load during pregnancy. Viral load rebound was defined as viral load >50 copies/mL (or >400 copies/mL for 1997 to 1998).

The researchers found that 318 of the 470 women in the database met inclusion criteria. Nineteen women (6 percent) had viral load rebound with a mean log10 viral load near delivery of 2.71 copies/mL (=513 copies/mL), while six women (32 percent) had a viral load above 1,000 copies/mL. In half of the women, rebound was detected within one day before delivery. Viral load rebound was significantly associated with aboriginal ethnicity, cocaine use, and hepatitis C virus polymerase chain reaction positivity. There were no HIV vertical transmissions.

"Even women attending for HIV care and achieving viral suppression in pregnancy can experience viral load rebound predelivery," the authors write.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Social, Communication Delays With False-Negative on M-CHAT

Social, Communication Delays With False-Negative on M-CHAT

Delays for those who pass M-CHAT screening at 18 months but are later diagnosed with ASD

FDA Approves Aimovig to Prevent Migraines

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo

Risk of Dementia Up for Older Adults With Lowest Wealth

Risk of Dementia Up for Older Adults With ...

Increased risk seen independent of education, index of multiple deprivation, health indicators

is free, fast, and customized just for you!

Already a member?

Sign In Now »